Drug delivery to the brain: how can nanoencapsulated statins be used in the clinic?. (July 2017)

• Record Type: Journal Article
• Authors: Sonvico, Fabio; Zimetti, Francesca; Pohlmann, Adriana Raffin; Guterres, Sílvia Stanisçuaski
• Is Part Of: Therapeutic delivery. Volume 8:Number 8(2017)
• Page Start: 625
• Page End: 631
• Publication Date: 2017-07
• Subjects: Alzheimer's disease -- drug delivery -- inflammation -- multiple sclerosis -- nanomedicine -- neuroprotection -- Parkinson's disease -- statin -- stroke; Drug delivery systems -- Periodicals; Therapeutics -- Periodicals; 615.6
• DOI: 10.4155/tde-2017-0044
• Languages: English
• ISSNs: 2041-5990

Abstract

Statins are used for the primary and secondary prevention of cardiovascular disease by inhibiting cholesterol synthesis in the liver. Statins have also noncholesterol-related effects, called pleiotropic effects, which arise from statins' anti-inflammatory, immunomodulatory and antioxidant properties. These effects are especially attractive for the treatment of various brain diseases ranging from stroke to neurodegenerative diseases. Still, low brain concentrations after oral drug administration hinder the clinical application of statins in these pathologies. Pharmaceutical nanotechnologies may offer a solution to this problem, as local or targeted delivery of nanoencapsulated statins may increase brain availability. This special report rapidly summarizes the potential of statins in the treatment of brain diseases and the pharmaceutical nanotechnologies that could provide a viable approach to enable these indications.